ANX005 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Guillain-Barre Syndrome
Conditions
Guillain-Barre Syndrome
Trial Timeline
Dec 17, 2020 → Apr 20, 2024
NCT ID
NCT04701164About ANX005 + Placebo
ANX005 + Placebo is a phase 3 stage product being developed by Annexon for Guillain-Barre Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04701164. Target conditions include Guillain-Barre Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04701164 | Phase 3 | Completed |
Competing Products
2 competing products in Guillain-Barre Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efgartigimod Alfa-Fcab + Intravenous Immunoglobulin (IVIg) | Argenx | Phase 2 | 49 |
| Tanruprubart | Annexon | Phase 3 | 72 |